Study summary
Hormone blockade shrank androgen-receptor-positive salivary cancers when two drugs were combined
45.2%response rate with darolutamide plus goserelin
What was tested
Darolutamide, a prostate cancer pill that blocks the androgen receptor, alone or with goserelin (which lowers testosterone), for androgen-receptor-positive salivary gland carcinoma.
What they found
- With darolutamide alone, 8.3% responded; with goserelin added, 45.2% responded.
- Median progression-free survival was 13.1 months with the combination.
- Side effects were mostly mild and quality of life was preserved.
What it means
A chemotherapy-free option for salivary duct carcinoma, which is often androgen-receptor-positive.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.